TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27395385

Group type: EXPERIMENTAL
Intervention: 10 g/day milk-containing LNS
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 20 g/day milk-containing LNS
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 40 g/day milk-containing LNS
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 20 g/day milk-free LNS
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 40 g/day milk-free LNS
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 1932
Study: 24122916

Group type: EXPERIMENTAL
Intervention: LIVE-IGS system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional IGS system
Number of subjects: 14
Study: 23301232

Group type: EXPERIMENTAL
Intervention: Tooth wipes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Toothbrushes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gauze
Number of subjects: 50
Study: 21079164

Group type: EXPERIMENTAL
Intervention: Skin prick test using Minolta CR‐400 Chromameter
Number of subjects: 46
Study: 18996231

Group type: EXPERIMENTAL
Intervention: Body‐weight‐supported treadmill walking for 20 minutes at 70% of estimated heart rate reserve
Number of subjects: 21

Group type: COMPARATOR
Intervention: 20‐minute review of a home exercise program with a physiotherapist
Number of subjects: 21
Study: 15992652

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily, vitamin C 1 g daily, and vitamin E 1,000 U daily
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 1005
Study: 12637120

Group type: EXPERIMENTAL
Intervention: Glimepiride (1 mg starting dose, titrated to 2 mg and 4 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10872928

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4.0 mg triamcinolone acetonide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Observation of untreated subjects
Number of subjects: 27
Study: 9360685

Group type: EXPERIMENTAL
Intervention: Cefazolin plus netilmycin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vancomycin plus ceftazidime
Number of subjects: 34
Study: 1319111

Group type: EXPERIMENTAL
Intervention: High-fiber diet (HFD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-fiber diet (LFD)
Number of subjects: 9
Study: 3897044

Group type: EXPERIMENTAL
Intervention: Low alcohol content beer (80% reduction in alcohol consumption for 6 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal alcohol consumption (336 ml of ethanol per week)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Reduction of alcohol intake
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Decrease in alcohol consumption from 350 ml to 70 ml per week
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Resumption of normal drinking habits
Number of subjects: 46
Study: 30329126

Group type: EXPERIMENTAL
Intervention: Telehealth‐based intervention delivered through 10 sessions each of 30 minutes over a 12‐week period with a wearable physical activity monitor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telehealth‐based education on nonbehavioral aspects of health for the same frequency and duration as the intervention group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telehealth‐based intervention
Number of subjects: 100
Study: 28695416

Group type: EXPERIMENTAL
Intervention: SCT constructs (exercise self-efficacy, exercise goal setting, multidimensional outcome expectations)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MS symptoms (walking limitations, fatigue, depression)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined SCT constructs and MS symptoms
Number of subjects: 65
Study: 27227290

Group type: EXPERIMENTAL
Intervention: Teflon infusion set in lipohypertrophied tissue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Teflon infusion set in nonlipohypertrophied tissue
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lipohypertrophied tissue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonlipohypertrophied tissue
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both lipohypertrophied and nonlipohypertrophied tissues
Number of subjects: 20
Study: 25027194

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (4 μg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV morphine (0.1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 21883510

Group type: EXPERIMENTAL
Intervention: Follicular aspiration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham aspirations
Number of subjects: 18
Study: 20403471

Group type: EXPERIMENTAL
Intervention: ACEI treatment at discharge
Number of subjects: 105224

Group type: EXPERIMENTAL
Intervention: ACEI treatment at discharge in patients without heart failure with renal dysfunction
Number of subjects: 105224
Study: 17914515

Group type: EXPERIMENTAL
Intervention: Suturing of the nasal septum after septoplasty
Number of subjects: 169

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 169
Study: 15643100

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) 600-1800 mg for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 40
Study: 12354174

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 16 weeks
Number of subjects: 3086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Patients with stable angina pectoris (SA)
Number of subjects: 3086

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 3086
Study: 10965249

Group type: EXPERIMENTAL
Intervention: Patients with POAG
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 150
Study: 9387637

Group type: EXPERIMENTAL
Intervention: Breathing exercises (BE)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo medicine (control)
Number of subjects: 324
Study: 1561022

Group type: EXPERIMENTAL
Intervention: 5.0 mg.kg‐1 caffeine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5 mg.kg‐1 caffeine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (200 mg. methylcellulose)
Number of subjects: 40
Study: 2861907

Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg/day before sleep)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28399620

Group type: EXPERIMENTAL
Intervention: Linolenic‐glutathione conjugate (Lin‐GSH) cream 2% before UVB irradiation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lin‐GSH cream 2% after irradiation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naïve arm (no treatment)
Number of subjects: 10
Study: 29354991

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Dazhui (GV 14), Mingmen (GV 4), Shenque (CV 8), Guanyuan (CV 4) with current intensity of (14±2) mA
Number of subjects: 89

Group type: COMPARATOR
Intervention: Simulated TEAS at the same acupoints with current intensity of 1 mA
Number of subjects: 89
Study: 25258425

Group type: EXPERIMENTAL
Intervention: Backward walking training (25 min/day, 3 days/week for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 30
Study: 23921615

Group type: EXPERIMENTAL
Intervention: LPV/r + RAL
Number of subjects: 210

Group type: COMPARATOR
Intervention: LPV/r + 2-3 N(t)RTIs
Number of subjects: 210
Study: 21527755

Group type: EXPERIMENTAL
Intervention: Telephone interview using the Barthel Index
Number of subjects: 131

Group type: COMPARATOR
Intervention: Face-to-face interview using the Barthel Index
Number of subjects: 131
Study: 18068523

Group type: EXPERIMENTAL
Intervention: Omega-3 FA supplementation (1 g eicosapentaenoic acid and 0.7 g docosahexaenoic acid daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 56
Study: 17173824

Group type: EXPERIMENTAL
Intervention: Asynchronous teledermatology (SAF)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Synchronous teledermatology (VTC)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional consult (CC)
Number of subjects: 159
Study: 12545342

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 0
Study: 10869914

Group type: EXPERIMENTAL
Intervention: Rewarming endpoint on CPB: nasopharyngeal and urinary bladder temperatures >/=36.5 degrees C and 34.0 degrees C
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rewarming endpoint on CPB: nasopharyngeal and urinary bladder temperatures >/=37.5 degrees C and 36.0 degrees C
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ambient OR temperature 16‐18 degrees C
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ambient OR temperature 21‐23 degrees C
Number of subjects: 72
Study: 9042685

Group type: EXPERIMENTAL
Intervention: Special one-year treatment including polyvitamins, N-acetylcysteine, and therapeutic BAL every 3 months (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 8275152

Group type: EXPERIMENTAL
Intervention: One-handed compressions
Number of subjects: 108

Group type: COMPARATOR
Intervention: Two-handed compressions
Number of subjects: 108
Study: 3437449

Group type: EXPERIMENTAL
Intervention: Peer-led social influences program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health consequences program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care comparison group
Number of subjects: 0
Study: 31740092

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF) + intramuscular Ketorolac
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (IVF) + intramuscular Ketorolac
Number of subjects: 220
Study: 29654308

Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate (LCD, 1.25 mmol/L Ca2+)
Number of subjects: 174

Group type: COMPARATOR
Intervention: High-calcium dialysate (HCD, 1.5 mmol/L Ca2+)
Number of subjects: 174
Study: 28387538

Group type: EXPERIMENTAL
Intervention: Structured informational and supportive meetings led by a palliative care physician and nurse practitioner.
Number of subjects: 51
Study: 25620200

Group type: EXPERIMENTAL
Intervention: Normal‐Abnormal category in the clinical trial cohort
Number of subjects: 93532

Group type: EXPERIMENTAL
Intervention: Normal‐Abnormal category in the observational study cohort
Number of subjects: 93532
Study: 23311688

Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg every 12 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sodium valproate 200 mg every 12 hours
Number of subjects: 104
Study: 21160307

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 162

Group type: COMPARATOR
Intervention: Open rectal cancer surgery
Number of subjects: 162
Study: 18811636

Group type: EXPERIMENTAL
Intervention: ED consent for telephone follow-up
Number of subjects: 430

Group type: COMPARATOR
Intervention: Telephone follow-up without prior ED consent
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 430
Study: 17165495

Group type: EXPERIMENTAL
Intervention: Pricking therapy (pricking thyroid gland high point)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (oral administration of tapazole)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pricking therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study: 14986593

Group type: EXPERIMENTAL
Intervention: Screening arm (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study: 11031698

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (lower doses than those used for aggressive tocolysis)
Number of subjects: 0
Study: 9382123

Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 205

Group type: COMPARATOR
Intervention: Uninformed consent
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Informed patients
Number of subjects: 205

Group type: COMPARATOR
Intervention: Uninformed patients
Number of subjects: 205
Study: 8282350

Group type: EXPERIMENTAL
Intervention: lisinopril (5, 10, or 20 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: metoprolol (50, 100, or 200 mg)
Number of subjects: 40
Study: 2727325

Group type: EXPERIMENTAL
Intervention: Instructions to think aloud
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Instructions to recall decision processes
Number of subjects: 60

Group type: COMPARATOR
Intervention: No instructions to verbalize
Number of subjects: 60
Study: 30274540

Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation
Number of subjects: 100
Study: 28100212

Group type: EXPERIMENTAL
Intervention: Nutrition-adequate breakfast
Number of subjects: 264

Group type: COMPARATOR
Intervention: Nutrition-inadequate breakfast
Number of subjects: 264

Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 264
Study: 26087670

Group type: EXPERIMENTAL
Intervention: Rituximab, 1,000 mg (2 infusions, 14 days apart; repeated at 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (CSA), 3.5‐5 mg/kg/day for 6 months (continued for another 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months)
Number of subjects: 0
Study: 23399373

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21098626

Group type: EXPERIMENTAL
Intervention: mF-G score greater than six (hirsutism)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: mF-G score of zero
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Increased total testosterone and HbA1(c) levels
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Decreased SHBG levels
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment for insulin resistance
Number of subjects: 1010
Study: 19325207

Group type: EXPERIMENTAL
Intervention: Orthodontic extrusive forces
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Orthodontic intrusive forces
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 17446337

Group type: EXPERIMENTAL
Intervention: Denufosol tetrasodium (20, 40, or 60 mg) administered three times daily for 28 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered three times daily for 28 days
Number of subjects: 89
Study: 14742349

Group type: EXPERIMENTAL
Intervention: Reflective or fluorescent clothing
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: White helmet
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Light coloured helmet
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Daytime headlight operation
Number of subjects: 463

Group type: COMPARATOR
Intervention: No reflective or fluorescent clothing
Number of subjects: 463

Group type: COMPARATOR
Intervention: Non-white helmet
Number of subjects: 463

Group type: COMPARATOR
Intervention: Dark coloured helmet
Number of subjects: 463

Group type: COMPARATOR
Intervention: No daytime headlight operation
Number of subjects: 463
Study: 11214054

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 60
Study: 9677789

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg e.v. every six hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7673950

Group type: EXPERIMENTAL
Intervention: High dose intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 6
Study: 2405864

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy (median dose 7.5 mg/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group) during low-dose methotrexate (MTX) therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (1 mg daily) during low-dose methotrexate (MTX) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study: 7431608

Group type: EXPERIMENTAL
Intervention: Polyvalent pneumococcal vaccine (Pneumovax) at baseline followed by saline placebo four weeks later.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Saline followed by polyvalent pneumococcal vaccine (Pneumovax).
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (10 volunteers) receiving polyvalent pneumococcal vaccine (Pneumovax).
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (diabetics and controls) receiving the vaccine.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (diabetics and controls).
Number of subjects: 50
Study: 31675664

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day for 6 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28455382

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 2474
Study: 24571538

Group type: EXPERIMENTAL
Intervention: Intervention group (preschool-based intervention to reduce screen time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 23046599

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) as induction therapy and thereafter as monthly infusions for 26 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) during induction therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo during maintenance therapy
Number of subjects: 62
Study: 20730514

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy for 1 year
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (matched subjects)
Number of subjects: 16
Study: 19430807

Group type: EXPERIMENTAL
Intervention: Cadence of 80 rpm at 60% W (max)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cadence of 50 rpm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cadence of 50, 65, 80, 95, and 110 rpm
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cadence of 80 rpm
Number of subjects: 18
Study: 16858182

Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin (400 mg q24 hours)
Number of subjects: 656

Group type: COMPARATOR
Intervention: IV piperacillin-tazobactam (3.0/0.375 g q6 hours) +/− PO amoxicillin-clavulanate (800 mg/114 mg q12 hours)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin
Number of subjects: 656

Group type: COMPARATOR
Intervention: IV piperacillin-tazobactam +/− PO amoxicillin-clavulanate
Number of subjects: 656
Study: 12482564

Group type: EXPERIMENTAL
Intervention: roxithromycin for 4 weeks after coronary stent placement
Number of subjects: 1010

Group type: COMPARATOR
Intervention: placebo for 4 weeks after coronary stent placement
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: C. pneumoniae‐specific IgG antibody levels
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: stratification by antibody levels
Number of subjects: 1010
Study: 10869578

Group type: EXPERIMENTAL
Intervention: Visual counting task
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Visuoperceptual tasks (identification of overlapping figures and discrimination of visual forms)
Number of subjects: 49
Study: 1869801

Group type: EXPERIMENTAL
Intervention: Maltodextrin containing oral rehydration salts (ORS) solution
Number of subjects: 69

Group type: COMPARATOR
Intervention: WHO recommended glucose‐ORS solution
Number of subjects: 69
Study: 6222704

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (5% lotion) applied twice daily for four weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hexachlorophene (3% colloidal suspension) applied twice daily for four weeks
Number of subjects: 9
Study: 30669704

Group type: EXPERIMENTAL
Intervention: Low protein-high fat diet (LP-HF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High protein-low fat diet (HP-LF)
Number of subjects: 12
Study: 28643570

Group type: EXPERIMENTAL
Intervention: Therapeutic instrumental music performance, 12 individual clinical contacts, twice weekly for six weeks.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Therapeutic instrumental music performance
Number of subjects: 11
Study: 27994711

Group type: EXPERIMENTAL
Intervention: PCC ECC system (Group I)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Noncoated ECC system (Group II)
Number of subjects: 32
Study: 25016604

Group type: EXPERIMENTAL
Intervention: Parent Motivation Inventory (PMI)
Number of subjects: 42
Study: 22068638

Group type: EXPERIMENTAL
Intervention: NIR spectroscopy added to traditional morphological evaluation
Number of subjects: 327

Group type: COMPARATOR
Intervention: Traditional morphological evaluation only
Number of subjects: 327
Study: 20543740

Group type: EXPERIMENTAL
Intervention: Wide-pronated grip
Number of subjects: 12

Group type: COMPARATOR
Intervention: Wide-supinated grip
Number of subjects: 12

Group type: COMPARATOR
Intervention: Narrow-pronated grip
Number of subjects: 12

Group type: COMPARATOR
Intervention: Narrow-supinated grip
Number of subjects: 12
Study: 18626566

Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 90

Group type: COMPARATOR
Intervention: HT alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HT + PTH(1‐84)
Number of subjects: 90
Study: 15921383

Group type: EXPERIMENTAL
Intervention: Locally adapted guidelines (GL) for VTE prophylaxis
Number of subjects: 500
Study: 12638327

Group type: EXPERIMENTAL
Intervention: DCM-R
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: DCM-NR
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 29
Study: 11561568

Group type: EXPERIMENTAL
Intervention: Levofloxacin 300 mg daily for 10 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ofloxacin 600 mg daily for 10 days
Number of subjects: 104
Study: 7486929

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 6